Gu-Hwan Kim

448 total citations
4 papers, 354 citations indexed

About

Gu-Hwan Kim is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Molecular Biology. According to data from OpenAlex, Gu-Hwan Kim has authored 4 papers receiving a total of 354 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Surgery, 4 papers in Endocrinology, Diabetes and Metabolism and 3 papers in Molecular Biology. Recurrent topics in Gu-Hwan Kim's work include Pancreatic function and diabetes (4 papers), Diabetes Treatment and Management (4 papers) and Metabolism, Diabetes, and Cancer (3 papers). Gu-Hwan Kim is often cited by papers focused on Pancreatic function and diabetes (4 papers), Diabetes Treatment and Management (4 papers) and Metabolism, Diabetes, and Cancer (3 papers). Gu-Hwan Kim collaborates with scholars based in Germany, United States and France. Gu-Hwan Kim's co-authors include Uli C. Broedl, H.J. Woerle, Julio Rosenstock, Cordula Zeller, Ante Jelaska, Afshin Salsali, Hans J. Woerle, Thomas Meinicke, Flavien Roux and Stefan Hantel and has published in prestigious journals such as Diabetic Medicine and Diabetes Obesity and Metabolism.

In The Last Decade

Gu-Hwan Kim

4 papers receiving 345 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gu-Hwan Kim Germany	4	340	198	168	60	24	4	354
Guillaume Frappin Switzerland	3	274 0.8×	148 0.7×	145 0.9×	47 0.8×	18 0.8×	5	329
Knut Robert Andersen Germany	5	344 1.0×	175 0.9×	162 1.0×	60 1.0×	20 0.8×	5	374
Masato Kawaguchi United States	5	457 1.3×	175 0.9×	224 1.3×	105 1.8×	22 0.9×	10	504
R. Qiu United States	3	463 1.4×	171 0.9×	231 1.4×	88 1.5×	19 0.8×	5	483
Azazuddin Ahmed Romania	6	489 1.4×	244 1.2×	204 1.2×	156 2.6×	25 1.0×	6	519
Ingrid Holst United States	3	337 1.0×	195 1.0×	69 0.4×	90 1.5×	8 0.3×	5	359
Laura Heenan United States	4	471 1.4×	165 0.8×	138 0.8×	114 1.9×	38 1.6×	7	532
Dawn Millington United States	6	202 0.6×	99 0.5×	117 0.7×	45 0.8×	12 0.5×	9	248
Jimmy Ren United States	4	374 1.1×	143 0.7×	173 1.0×	57 0.9×	43 1.8×	8	439
Milivoj Piletič Denmark	6	435 1.3×	256 1.3×	104 0.6×	86 1.4×	4 0.2×	10	461

Countries citing papers authored by Gu-Hwan Kim

Since Specialization

Citations

This map shows the geographic impact of Gu-Hwan Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gu-Hwan Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gu-Hwan Kim more than expected).

Fields of papers citing papers by Gu-Hwan Kim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gu-Hwan Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gu-Hwan Kim. The network helps show where Gu-Hwan Kim may publish in the future.

Co-authorship network of co-authors of Gu-Hwan Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Gu-Hwan Kim. A scholar is included among the top collaborators of Gu-Hwan Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gu-Hwan Kim. Gu-Hwan Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

4 of 4 papers shown

1.

Salsali, Afshin, Gu-Hwan Kim, Hans J. Woerle, Uli C. Broedl, & Stefan Hantel. (2016). Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta‐analysis of data from randomized placebo‐controlled trials. Diabetes Obesity and Metabolism. 18(10). 1034–1040. 35 indexed citations

2.

Merker, Ludwig, H.-U. Häring, Anita Vedel Christiansen, et al.. (2015). Empagliflozin as add‐on to metformin in people with Type 2 diabetes. Diabetic Medicine. 32(12). 1555–1567. 68 indexed citations

3.

Araki, Eiichi, Yukio Tanizawa, Yuko Tanaka, et al.. (2015). Long‐term treatment with empagliflozin as add‐on to oral antidiabetes therapy in J apanese patients with type 2 diabetes mellitus. Diabetes Obesity and Metabolism. 17(7). 665–674. 50 indexed citations

4.

Rosenstock, Julio, Ante Jelaska, Cordula Zeller, et al.. (2015). Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial. Diabetes Obesity and Metabolism. 17(10). 936–948. 201 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact